News >

NEJM Data Show Luspatercept Alleviates Anemia in Patients With MDS

Brittany Cote
Published: Tuesday, Jan 14, 2020

Habib Dable, president and chief executive officer of Acceleron

Habib Dable

Treatment with luspatercept-aamt (Reblozyl) reduced the severity of anemia in patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts who require red blood cell (RBC) transfusions, according to findings from the phase III MEDALIST trial that have now been published in the New England Journal of Medicine (NEJM).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication